Form 4: Soleno Therapeutics CFO Sells Shares to Cover Tax Obligations

James H. Mackaness, CFO of Soleno Therapeutics Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On October 1, 2024, James H. Mackaness, the Chief Financial Officer of Soleno Therapeutics Inc., sold shares of the company's common stock.
• A total of 7,248 shares were sold at a weighted average price of $49.3358, with individual prices ranging from $48.95 to $49.94.
• An additional 829 shares were sold at a weighted average price of $50.2479, with individual prices ranging from $49.95 to $50.49.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Mackaness directly owns 119,172 shares of Soleno Therapeutics Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sale appears to be for tax obligations related to vested RSUs, which is a common practice and doesn't necessarily reflect a change in the CFO's confidence in the company.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock and future prospects. However, sales to cover tax obligations are common and do not necessarily indicate a negative outlook.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on shareholders due to the increased selling pressure.
• The impact on employees is likely minimal, as the transaction is related to executive compensation and tax obligations.

Key Dates